Mechanisms of Macrolide Resistance in Clinical Pneumococcal Isolates in a University Hospital, Ankara, Turkey

References

• Leclerq R, Courvalin P. Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46: 2727–34.
   PubMed Web of Science ®Google Scholar
• Weisblum B. Erythromycin resistance by ribosome modi-fication. Antimicrob Agents Chemother 1995; 39: 577–85.
   PubMed Web of Science ®Google Scholar
• Sutcliffe JA, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996; 40: 1817–24.
   PubMed Web of Science ®Google Scholar
• Inoue M, Lee NY, Hong SW, Lee K, Felmingham D. PROTEKT 1999-2000: a multicentre study of the antibiotic susceptibility of respiratory tract pathogens in Hong Kong, Japan and South Korea. Int J Antimicrob Agents 2004; 23: 44–51.
   Google Scholar
• Tait-Kamradt A, Davies T, Appelbaum PC et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000; 44: 3395–401.
   PubMed Web of Science ®Google Scholar
• Sener B, analp A. Trends in antimicrobial resistance of Streptococcus pneumoniae in children in a Turkish hospital. J Antimicrob Chemother 1998; 42: 381–84.
   Google Scholar
• Gar D, Güçiz B, HaKelik G et al. Streptococcus pneu-moniae penicillin resistance in Turkey. J Chemother 2001; 13: 541–45.
   Google Scholar
• Sener B, Köseoglu O. Comparative in-vitro activity of antiribosomal agents on penicillin susceptible and resistant Streptococcus pneumoniae in relation to their resistance phe-notypes. Int J Antimicrob Agents 2004; 24: 39–42.
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. (2000). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th. Edition: Approved stan-dard M7-A5. NCCLS, Wayne, PA, USA.
   Google Scholar
• Smith AM, Klugman KP, Coffey TJ, Spratt BC. Genetic diversity of penicillin-binding protein 2B and 2X genes from Streptococcus pneumoniae in South Africa. Antimicrob Agents Chemother 1993; 37: 1938–1944.
   PubMed Web of Science ®Google Scholar
• Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L. Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother 1996; 40: 2562–2566.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Palatnick L, Nichol KA, Bellyou T, Low DE, Hoban DJ. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47: 1867–74.
   PubMed Web of Science ®Google Scholar
• Pihlajamaki M, Jalava J, Huovinen P, Kotilainen P, Finnish Study Group for Antimicrobial Resistance. Antimicrobial resistance of invasive pneumococci in Finland in 1999-2000. Antimicrob Agents Chemother 2003; 47: 1832–35.
   Google Scholar
• Kozlov RS, Bogdanovitch TM, Appelbaum PC et al. Antistreptococcal activity of telithromycin compared with seven other drugs in relation to macrolide resistance mecha-nisms in Russia. Antimicrob Agents Chemother 2002; 46: 2963–68.
   PubMed Web of Science ®Google Scholar
• Baquero F, Garcia Rodriguez JA, Garcia de Lomas J, Aguilar L & the Spanish Surveillance Group for Respiratory Tract Pathogens. Antimicrobial resistance of 1113 Streptococcus pneumoniae isolates from patients with respi-ratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study. Antimicrob Agents Chemother 1999; 43: 357–359.
   Google Scholar
• Oster P, Zanchi A, Cresti S. Patterns of macrolide resistance determinants among community acquired Streptococcus pneumoniae isolates over a 5-year period of decreased macrolide susceptibility rates. Antimicrob Agents Chemother 1999; 43: 2510–12.
   PubMed Web of Science ®Google Scholar
• Doern CV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect 2004; 48: 56–65.
   PubMed Web of Science ®Google Scholar
• Song JH, Chang HH, Suh JY et al. Macrolide resis-tance and genotypic characterization of Streptococcus pneu-moniae in Asian countries: a study of the Asian Network for Surveillance of Resistant Pathogens (ANSORP). J Antimicrob Chemother 2004; 53: 457–63.
   Google Scholar
• Fitoussi F, Doit C, Geslin P, Brahimi N, Bingen E. Mechanisms of macrolide resistance in clinical pneumococcal isolates in France. Antimicrob Agents Chemother 2001; 45: 636–38.
   PubMed Web of Science ®Google Scholar
• Baquero, F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption. Journal of Chemotherapy 1999; 11 (Suppl. 1), 35-43.
   Google Scholar
• Reinert RR, Wild A, Appelbaum P, Lutticken R, Cil MY, Al-Lahham A. Ribosomal mutations conferring resistance to macrolides in Streptococcus pneumoniae clinical strains isolated in Germany. Antimicrob Agents Chemother 2003; 47: 2319–22.
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Douthwaite S, Morrissey I et al. Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study. Antimicrob Agents Chemother 2003; 47: 1777–83.
   Google Scholar
• Shortridge VD, Doern GV, Brueggemann AB, Beyer JM, Flamm RK. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicen-ter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis 1999; 29: 1186–88.
   PubMed Web of Science ®Google Scholar
• Morosini MI, Canton R, Loza E et al. In vitro activity of telithromycin against Spanish Streptococcus pneumoniae iso-lates with characterized macrolide resistance mechanisms. Antimicrob Agents Chemother 2001; 45: 2427–31.
   Google Scholar
• Douthwaite S, Champney WS. Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site. J Antimicrob Chemother 2001; 48: (Suppl T1),1–8.
   PubMedGoogle Scholar
• Sutcliffe J. Resistance to macrolides mediated by efflux mechanisms. Curr Opin Invest Drugs 1999; 1: 403–12.
   Google Scholar